Merete Bjornslett

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

BRCA mutation testing and association with oncologic outcome and incidence of ovarian cancer in Norway.

BRCA mutation testing and association with oncologic outcome and incidence of ovarian cancer in Norway.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 19, 2024

Evolutionary mode and timing of dissemination of high-grade serous carcinomas.

Evolutionary mode and timing of dissemination of high-grade serous carcinomas.

Journal: JCI insight

Published: December 21, 2023

E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models.

E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models.

Journal: Molecular oncology

Published: August 17, 2021

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.

Journal: Scientific reports

Published: June 02, 2021

Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer.

Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer.

Journal: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals

Published: March 01, 2021

Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer.

Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer.

Journal: ESMO open

Published: September 11, 2020

Genomic and prognostic heterogeneity among RAS/BRAFV600E /TP53 co-mutated resectable colorectal liver metastases.

Genomic and prognostic heterogeneity among RAS/BRAFV600E /TP53 co-mutated resectable colorectal liver metastases.

Journal: Molecular oncology

Published: September 03, 2020

A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis.

A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: January 04, 2020

Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2.

Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2.

Journal: Laboratory investigation; a journal of technical methods and pathology

Published: August 21, 2019

White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.

White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.

Journal: Annals of internal medicine

Published: January 17, 2018

Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.

Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.

Journal: Molecular cancer

Published: April 05, 2017

C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.

C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.

Journal: PloS one

Published: March 27, 2017

Showing 1-12 of 17

Last Updated: 09/26/2026